Rakovina Therapeutics Inc. (TSXV:RKV)

Canada flag Canada · Delayed Price · Currency is CAD
0.135
-0.005 (-3.57%)
At close: Mar 9, 2026
-91.00%
Market Cap 2.85M
Revenue (ttm) n/a
Net Income (ttm) -8.28M
Shares Out 21.15M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,656
Average Volume 23,155
Open 0.135
Previous Close 0.140
Day's Range 0.135 - 0.135
52-Week Range 0.085 - 1.500
Beta -0.65
RSI 44.40
Earnings Date Apr 28, 2026

About Rakovina Therapeutics

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Varia... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Kim Oishi
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol RKV
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.